# Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

Source: https://onco.cc/trials/nct04475523/  
OnCo record `nct04475523` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CI-8993 run by Curis, Inc., completed.

## Summary

Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies is a phase 1 interventional study registered as NCT04475523 by Curis, Inc., with 26 participants enrolled, started 2020-09-22. Conditions recorded: Solid Tumor. Interventions recorded: CI-8993.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04475523
- Phase: 1
- Setting: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
- Sponsor: Curis, Inc.
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT04475523: https://clinicaltrials.gov/study/NCT04475523

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [CI-8993](https://onco.cc/drugs/ci-8993/)
- companies: [Curis](https://onco.cc/companies/curis/), [ImmuNext](https://onco.cc/companies/immunext/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct04475523.json